| Literature DB >> 35010180 |
Amer Ali Mahdi1,2, Qais Ali Al-Maqtari2,3, Jalaleldeen Khaleel Mohammed3, Waleed Al-Ansi2,3, Sahibzada Muhammad Aqeel4, Haiying Cui1, Lin Lin1,5.
Abstract
This study evaluates the combined efficiency of whey protein isolate (WPI) with maltodextrin (MD) and gum arabic (GA), as a delivery system for encapsulating Citrus reticulata essential oil (CEO). The wall materials blended at different rates were produced to obtain seven formulations of nanocapsules (NCEO), namely NCEO-GA, NCEO-MD, NCEO-WPI, NCEO-GA/MD, NCEO-GA/WPI, NCEO-MD/WPI, and NCEO-GA/MD/WPI. The interaction between CEO and WPI was simulated by molecular docking. Findings showed that the physicochemical characteristics and storage stability of formulations containing WPI were considerably improved. The NCEO-GA/MD/WPI formulation demonstrated the optimum values of encapsulation efficiency (92.08%), highest glass transition temperature (79.11 °C), high crystallinity (45.58%), high thermal stability (mass loss at 100 °C < 5%), and also had the highest antioxidant activity and lowest peroxide value after storage. This study demonstrated that combining WPI with MD and GA, as wall material encapsulation, can produce nanocapsules with superior properties to those created using polysaccharides individually.Entities:
Keywords: Citrus reticulata; encapsulation wall materials; molecular docking; nanoencapsulation
Year: 2021 PMID: 35010180 PMCID: PMC8750011 DOI: 10.3390/foods11010054
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Formulation of the aqueous phase of Citrus reticulata essential oil nanoemulsions.
| Formulations Code | Gum Arabic (g) | Maltodextrin (g) | Whey Protein Isolate (g) | Water (g) |
|---|---|---|---|---|
| NCEO-GA | 24 | - | - | 68 |
| NCEO-MD | - | 24 | - | 68 |
| NCEO-WPI | - | - | 24 | 68 |
| NCEO-GA/MD | 12 | 12 | - | 68 |
| NCEO-GA/WPI | 12 | - | 12 | 68 |
| NCEO-MD/WPI | - | 12 | 12 | 68 |
| NCEO-GA/MD/WPI | 8 | 8 | 8 | 68 |
GA formulation (NCEO-GA); MD formulation (NCEO-MD); WPI formulation (NCEO-WPI); GA/MD formulation (NCEO-GA/MD); GA/WPI formulation (NCEO-GA/WPI); MD/WPI formulation (NCEO-MD/WPI); GA/MD/WPI formulation (NCEO-GA/MD/WPI); and - (0 g).
MSD, PDI, and ζ-potential of fresh emulsions.
| Emulsions’ Code | MSD (nm) | PDI | Zeta-Potential (mV) |
|---|---|---|---|
| GA-based | 674.18 ± 10.07 a | 0.26 ± 0.03 a | −58.08 ± 0.28 b |
| MD-based | 628.59 ± 13.5 b | 0.23 ± 0.03 ab | −57.48 ± 0.24 a |
| WPI-based | 357.86 ± 12.39 e | 0.17 ± 0.05 c | −57.64 ± 0.33 ab |
| GA/MD-based | 578.58 ± 8.02 c | 0.25 ± 0.03 ab | −57.66 ± 0.26 ab |
| GA/WPI-based | 527.12 ± 8.25 d | 0.23 ± 0.04 ab | −57.69 ± 0.28 ab |
| MD/WPI-based | 372.18 ± 8.29 e | 0.23 ± 0.04 ab | −57.75 ± 0.26 ab |
| GA/MD/WPI-based | 529.64 ± 15.51 d | 0.20 ± 0.04 bc | −57.75 ± 0.28 ab |
The data are shown as the mean ± SD (n = 3). In the same column, the different letters indicate that the data is significantly different (p ≤ 0.05).
Encapsulation efficiency, particle size, and polydispersity index (PDI) of CEO nanocapsules.
| Formulations | Encapsulation Efficiency (%) | Particle Size (nm) | PDI |
|---|---|---|---|
| NCEO-GA | 37.17 ± 3.16 d | 782.09 ± 58.66 a | 0.47 ± 0.04 d |
| NCEO-MD | 36.29 ± 2.90 d | 695.49 ± 52.16 abc | 0.41 ± 0.03 c |
| NCEO-WPI | 65.55 ± 5.90 c | 427.35 ± 32.05 d | 0.26 ± 0.02 a |
| NCEO-GA/MD | 43.04 ± 3.23 d | 738.51 ± 55.39 ab | 0.36 ± 0.03 bc |
| NCEO-GA/WPI | 78.22 ± 6.65 b | 641.79 ± 48.13 c | 0.32 ± 0.02 b |
| NCEO-MD/WPI | 69.03 ± 4.83 c | 430.35 ± 32.28 d | 0.27 ± 0.02 a |
| NCEO-GA/MD/WPI | 92.08 ± 6.45 a | 674.95 ± 50.62 bc | 0.38 ± 0.03 c |
The data are shown as the mean ± SD (n = 3). In the same column, the different letters indicate that the data is significantly different (p ≤ 0.05).
Moisture, hygroscopicity, solubility, and wettability of CEO nanocapsules.
| Formulations | Moisture (%) | Hygroscopicity (%) | Solubility (%) | Wettability (s) |
|---|---|---|---|---|
| NCEO-GA | 5.71 ± 0.37 a | 12.90 ± 0.77 cd | 81.87 ± 3.68 b | 247.3 ± 17.5 c |
| NCEO-MD | 3.87 ± 0.29 c | 14.63 ± 0.95 ab | 93.58 ± 4.68 a | 108.0 ± 10.0 f |
| NCEO-WPI | 4.31 ± 0.26 c | 12.21 ± 0.61 d | 89.61 ± 4.93 ab | 305.3 ± 25.0 a |
| NCEO-GA/MD | 3.95 ± 0.26 c | 13.94 ± 0.77 abc | 84.12 ± 3.79 b | 172.0 ± 9.20 e |
| NCEO-GA/WPI | 4.12 ± 0.31 c | 15.42 ± 0.93 a | 83.25 ± 4.16 b | 286.0 ± 10.0 b |
| NCEO-MD/WPI | 3.93 ± 0.28 c | 12.05 ± 0.72 d | 86.51 ± 4.33 ab | 223.0 ± 14.4 d |
| NCEO-GA/MD/WPI | 4.98 ± 0.35 b | 13.84 ± 0.90 bc | 87.55 ± 4.82 ab | 242.3 ± 0.39 cd |
The data are shown as the mean ± SD (n = 3). In the same column, the different letters indicate that the data is significantly different (p ≤ 0.05).
Bulk, tapped, and particle density of CEO nanocapsules.
| Formulations | Bulk Density | Tapped Density | Particle Density |
|---|---|---|---|
| NCEO-GA | 0.26 ± 0.03 c | 0.43 ± 0.04 c | 1.79 ± 0.06 b |
| NCEO-MD | 0.26 ± 0.03 c | 0.46 ± 0.04 bc | 1.56 ± 0.08 c |
| NCEO-WPI | 0.36 ± 0.04 a | 0.50 ± 0.04 ab | 1.96 ± 0.09 a |
| NCEO-GA/MD | 0.28 ± 0.03 c | 0.52 ± 0.04 a | 1.67 ± 0.08 bc |
| NCEO-GA/WPI | 0.36 ± 0.04 a | 0.52 ± 0.05 a | 1.61 ± 0.06 c |
| NCEO-MD/WPI | 0.36 ± 0.03 a | 0.54 ± 0.05 a | 1.67 ± 0.09 bc |
| NCEO-GA/MD/WPI | 0.32 ± 0.04 b | 0.52 ± 0.04 a | 1.67 ± 0.06 bc |
The data are shown as the mean ± SD (n = 3). In the same column, the different letters indicate that the data is significantly different (p ≤ 0.05).
Porosity, Carr’s index, Hausner ratio, and flowability of CEO nanocapsules.
| Formulations | Porosity (%) | Carr’s Index (%) | Hausner Ratio | Flowability |
|---|---|---|---|---|
| NCEO-GA | 75.86 ± 3.79 a | 38.95 ± 1.95 b | 1.64 ± 0.08 bc | Awful |
| NCEO-MD | 72.22 ± 3.97 abc | 43.75 ± 2.41 a | 1.78 ± 0.10 ab | Awful |
| NCEO-WPI | 74.45 ± 3.35 ab | 28.57 ± 1.29 d | 1.40 ± 0.06 d | Poor |
| NCEO-GA/MD | 68.75 ± 3.44 bc | 45.45 ± 2.27 a | 1.83 ± 0.09 a | Awful |
| NCEO-GA/WPI | 68.00 ± 3.74 bc | 30.00 ± 1.65 d | 1.43 ± 0.08 d | Poor |
| NCEO-MD/WPI | 67.39 ± 3.03 c | 34.29 ± 1.54 c | 1.52 ± 0.07 cd | Very poor |
| NCEO-GA/MD/WPI | 66.69 ± 3.33 c | 37.66 ± 1.88 b | 1.60 ± 0.08 c | Very poor |
The data are shown as the mean ± SD (n = 3). In the same column, the different letters indicate that the data is significantly different (p ≤ 0.05).
Color parameters of CEO nanocapsules.
| Formulations | L* | a* | b* | ΔE* |
|---|---|---|---|---|
| NCEO-GA | 92.31 ± 0.20 d | 0.42 ± 0.01 e | 8.92 ± 0.12 c | 8.26 ± 0.12 c |
| NCEO-MD | 95.36 ± 0.20 f | −1.00 ± 0.11 a | 4.18 ± 0.29 a | 4.35 ± 0.21 a |
| NCEO-WPI | 88.69 ± 0.09 a | −0.13 ± 0.02 d | 22.64 ± 0.19 f | 22.23 ± 0.17 f |
| NCEO-GA/MD | 93.29 ± 0.08 e | −0.16 ± 0.01 d | 6.90 ± 0.05 b | 6.20 ± 0.04 b |
| NCEO-GA/WPI | 89.83 ± 0.18 b | 0.41 ± 0.04 e | 16.48 ± 0.71 e | 16.01 ± 0.73 e |
| NCEO-MD/WPI | 91.61 ± 0.25 c | −0.75 ± 0.04 b | 16.58 ± 0.57 e | 15.83 ± 0.59 e |
| NCEO-GA/MD/WPI | 93.52 ± 0.07 e | −0.35 ± 0.08 c | 11.39 ± 0.22 d | 10.66 ± 0.21 d |
The data are shown as the mean ± SD (n = 3). In the same column, the different letters indicate that the data is significantly different (p ≤ 0.05). Lightness (L*), redness (a*), yellowness (b*), and the total color difference (ΔE*).
Figure 1TG and DTG curves of the CEO nanocapsules.
Figure 2XRD diffraction patterns of the CEO nanocapsules.
Figure 3Molecular docking simulation of D-Limonene with β-lactoglobulin. The 3D structure of D-Limonene (a), 3D structure of β-lactoglobulin (b), 2D diagram of the interactions between D-Limonene with β-lactoglobulin amino acids (c), and the 3D diagram of β-lactoglobulin/D-Limonene (d).
Figure 4Morphology of the CEO nanocapsules by scanning electron microscopy (SEM).
Figure 5Antioxidant activity stability by DPPH assay (a), antioxidant capacity stability by ABTS assay (b), and oxidative stability (c) of CEO nanocapsules. The results are expressed as the mean ± standard deviation (n = 3). Different lower-case letters (a–f) indicate the significant differences (p ≤ 0.05) between the stored nanocapsules at 5 °C, and upper-case letters (A–E) indicate the significant differences between the stored nanocapsules at 50 °C.